Pneumonia in immunocompetent patients: Combination antibiotic therapy

Minerva Anestesiologica

Volumn 80, Issue 4, 2014, Pages 495-503

  Salva, S ^a   Borgatta, B ^b   Rello, J ^b,c,d  

^a Vail d'Hebron University Hospital   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Combined modality therapy; Pneumonia; Sepsis; Shock

Indexed keywords

AMINOGLYCOSIDE; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; ERTAPENEM; LINEZOLID; MACROLIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CLINICAL TRIAL (TOPIC); COMMUNITY ACQUIRED PNEUMONIA; CRITICALLY ILL PATIENT; DISEASE SEVERITY; GRAM NEGATIVE INFECTION; HEALTH CARE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; IMMUNOCOMPROMISED PATIENT; MONOTHERAPY; MORTALITY; NOTE; RESUSCITATION; SEPSIS; SHOCK; THERAPY; VENTILATOR ASSOCIATED PNEUMONIA; ALGORITHM; CROSS INFECTION; DRUG COMBINATION; IMMUNOCOMPETENCE; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED;

ALGORITHMS; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOCOMPETENCE; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 84901458068     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (50)

1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al.; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10. (Pubitemid 32641789)
3. Textoris J, Wiramus S, Martin C, Leone M. Overview of antimicrobial therapy in intensive care units. Expert Rev Anti Infect Ther 2011;9:97-109.
4. Legrand M, Max A, Schlemmer B, Azoulay E, Gachot B. The strategy of antibiotic use in critically ill neutropenic patients. Ann Intensive Care 2011;1:22.
5. Micek S, Johnson MT, Reichley R, Kollef MH. An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis. BMC Infect Dis2012;13:12:56.
6. Torres A, Rello J. Update in community-acquired and nosocomial pneumonia 2009. Am J Respir Crit Care Med. 2010;181:782-87.
7. Pereira JM, Paiva JA, Rello J. Severe sepsis in community-acquired pneumonia - early recognition and treatment. Eur J Intern Med 2012; 23:412-19.
8. Falcó V, Sánchez A, Pahissa A, Rello J. Emerging drugs for pneumococcal pneumonia. Expert Opin Emerg Drugs. 2011; 16:459-77.
9. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012 Jan;67:71-9.
10. Ott SR, Hauptmeier BM, Ernen C, Lepper PM, Nüesch E, Pletz MW, Hecht J, et al. Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis. Eur Respir J. 2012;39:611-18.
11. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44 (Suppl 2):S27-72 (Pubitemid 46290553)
12. Caballero J, Rello J. Combination antibiotic therapy for community-acquired pneumonia. Ann Intensive Care. 2011; 1:48-54.
13. Rello J, Lisboa T, Lujan M, Gallego M, Kee C, Kay I, Lopez D, Waterer GW; DNA-Neumococo Study Group. Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest 2009;136:832-40.
14. Ulldemolins M, Roberts JA, Lipman MD, Rello J: Antibiotic dosing in multiple organ dysfunction syndrome. Chest 2011; 139:1210-20.
15. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011 Feb;50(2):99-110
16. Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, et al Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med. 2010; 38:1773-85.
17. Rodríguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Sole-Violan J, et al. CAPUCI Study Group: Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007; 35:1493-98. (Pubitemid 46809312)
18. Harbarth S, Garbino J, Pugin J, Romand JA, Pittet D. Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis. 2005;10:688-90. (Pubitemid 41667057)
19. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;15:1837-42.
20. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortgvist A, Rello J, et al. International Pneumococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170: 440-44 (Pubitemid 39214620)
21. Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, et al. MOTIV (MOxifloxacin Treatment IV) Study Group. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study - a randomized clinical trial. Clin Infect Dis. 2008; 46:1499-509. (Pubitemid 351706729)
22. Ambroggio L, Taylor JA, Tabb LP, Newschaffer CJ, Evans AA, Shah SS. Comparative Effectiveness of Empiric β-Lactam Monotherapy and β-Lactam-Macrolide Combination Therapy in Children Hospitalized with Community-Acquired Pneumonia. J Pediatr 2012; Aug. [Epub ahead of print]
23. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009; 33:153-59.
24. Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 2007; 51:3977-82. (Pubitemid 350057796)
25. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Chest 2007; 131:466-73. (Pubitemid 46280407)
26. Rello J, Gattarello S, Souto J, Sole-Violan J, Valles J, Peredo R, et al. The Community-Acquired Pneumonia in Unidad de Cuidados Intensivos 2 (CAPUCI 2) Study Investigators. Community-acquired Legionella Pneumonia in the intensive care unit: Impact on survival of combined antibiotic therapy. Med Intensiva. 2012 Jul 30. [Epub ahead of print]
27. Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho-Montero J, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010; 36:612-20.
28. Lin E, Stanek RJ, Mufson MA: Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumonia in vitro. Antimicrob Agents Chemother 2003; 47:1151-53. (Pubitemid 36254253)
29. Takizawa H, Desaki M, Ohtoshi T. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997; 156:266-71 (Pubitemid 27293200)
30. Giamarellos-Bourboulis EJ. Immunomodulatory therapies for sepsis: unexpected effects with macrolides. Int J Antimicrob Agents 2008; 32: S39-43.
31. Bliziotis IA, Petrosillo N, Michalopoulos A, Samonis G, Falagas ME. Impact of Definitive Therapy with Beta-Lactam Monotherapy or Combination with an Aminoglycoside or a Quinolone for Pseudomonas aeruginosa Bacteremia. PLoS ONE 2011;6: e26470.
32. Harbarth S, Nobre V, Pittet D. Does antibiotic selection impact patient outcome? Clin Infect Dis 2007; 44: 87-93. (Pubitemid 44968991)
33. Mutlu GM, Wunderink RG. Severe pseudomonal infections. Curr Opin Crit Care 2006; 12: 458-463. (Pubitemid 44341713)
34. Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH: Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med 2011;39:46-51.
35. Micek S, Johnson MT, Reichley R, Kollef MH. An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis. BMC Infect Dis 2012; 12:56.
36. American Thoracic Society Documents. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am J Respir Crit Care Med Vol 171. pp 388-416, 2005
37. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85.
38. Osmon S, Ward S, Fraser VJ, Kollef MH. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest 2004; 125: 607-16. (Pubitemid 38223643)
39. Parkins MD, Gregson DB, Pitout JD, Ross T, Laupland KB. Population based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection. Infection 2010; 38: 25-32.
40. Martin-Loeches I, Deja M, Koulenti D, Dimopoulos G, Marsh B, Torres A, Niederman MS, Rello J; EU-VAP Study Investigators. Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med. 2013;39:672-81.
41. Magret M, Amaya-Villar R, Garnacho J, Lisboa T, Díaz E, Dewaele J, Deja M, Manno E, Rello J; EU-VAP/CAP Study Group. Ventilator-associated pneumonia in trauma patients is associated with lower mortality: results from EU-VAP study. J Trauma 2010; 69:849-54.
42. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519-527. (Pubitemid 39077923)
43. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87: 540-46. (Pubitemid 19274758)
44. Garnacho-Montero, Sa-Borges J, Sole-Violan F, Barcenilla A, Escoresca-Ortega M, Ochoa M. et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Critical Care Medicine 2007; 35:1888-95
45. Pletz MW, Burkhardt O, Welte T. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy. Eur J Med Res. 2010;15:507-13.
46. Rello J, Nieto M, Solé J, Wan Y, Gao X, Solem CT, De Salas-Cansado M, Trikic M, Charbonneau C, Chastre J. Spanish economic analysis of resource-use burden among patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA-NP) treated with linezolid or vancomycin, with a special focus on patients developing renal failure. 23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin 2013, P855 Abstract.
47. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta- regression study. Crit Care Med 2010; 38:1651-64
48. Martinez JA, Cobos-Trigueros N, Soriano A, Almela M, Ortega M, et al. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother 2010; 54: 3590-96.
49. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia. Antimicrob Agents Chemother. 2013;57:1756-62.
50. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012; 55:943-50.